KRAS and non-small cell lung carcinoma: ,11 In a retrospective series (N = 189), incidence and time to first SRE were similar between patients with EGFR+, KRAS+, and EGFR/KRAS wild-type NSCLC when treated with first-/second-generation EGFR TKI or chemotherapy, respectively.1